[{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"B. Braun Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"B. Braun Medical \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"ProvideGx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Inc \/ ProvideGx","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ ProvideGx"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit","highestDevelopmentStatusID":"11","companyTruncated":"University of Melbourne \/ Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"11","companyTruncated":"Hamilton Health Sciences \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Totacef

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 23, 2024

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Canadian Institutes of Health Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 04, 2022

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          January 25, 2022

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          University of Melbourne

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          University of Melbourne

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 30, 2021

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : The three medicines include cefazolin, cefepime and ceftriaxone for injection and are part of the cephalosporin category of antibiotics. Cephalosporins are one of the most widely prescribed classes of medications in the world and treat a variety of bacte...

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          August 02, 2021

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : ProvideGx

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Sonescence, Inc.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Sonescence, Inc.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 06, 2018

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : University of Southern California

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Mercy Health

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Mercy Health

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 18, 2018

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          July 27, 2017

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 06, 2014

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Physician Services Incorporated

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          July 22, 2013

                          Lead Product(s) : Cefazolin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank